Abstract：Objective To explore the effect and safety of Anlotinib combined with chemotherapy in the treatment of non-small cell lung cancer (NSCLC).Methods A total of 57 patients with advanced NSCLC (third-line) diagnosed by the First Department of Oncology, People′s Hospital of Liaoning Province from July 2018 to January 2019 were selected as the research objects, and the patients were divided into observation group (29 cases) and control group (28 cases) by the random number table method.The control group was treated with conventional chemotherapy and symptomatic treatment, and the observation group was given oral Anlotinib Hydrochloride Capsules 12 mg/(times·d) for two weeks on the basis of conventional chemotherapy, with one week of withdrawal, three weeks as a treatment cycle, and the efficacy was evaluated at the sixth week.The clinical efficacy, survival indicators and incidence of adverse reactions were compared between the two groups.Results The disease control rate of the observation group was higher than that of the control group, and the difference was statistically significant (P＜0.05).The progression-free survival of the observation group was longer than that of the control group, and the difference was statistically significant (P＜0.05).The overall survival in the observation group was longer than that in the control group, and the difference was statistically significant(P＜0.05).The main adverse reactions were abnormal liver function, anorexia, nausea and vomiting, leukopenia, abnormal renal function, thrombocytopenia, fatigue, diarrhea and bleeding.There was no statistically significant difference in the incidence rate of adverse reactions between the two groups (P ＞0.05).Conclusion Anrotinib combined with chemotherapy for the treatment of NSCLC can effectively control the development of the disease, prolong the survival time of patients, and has good safety.
王晓舟；李洪石；于溪；王梓瑛；赫丽杰. 安罗替尼联合化疗治疗非小细胞肺癌的效果及安全性[J]. 中国当代医药, 2021, 28(8): 81-83转88.
WANG Xiao-zhou；LI Hong-shi；YU Xi WANG Zi-ying；HE Li-jie. Effect and safety of Anlotinib combined with chemotherapy in the treatment of non-small cell lung cancer. 中国当代医药, 2021, 28(8): 81-83转88.
Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin，2018，68（6）：394-424.
[2]
Chen Z，Zhong B，Lun X，et al.Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC：A Meta-Analysis[J].Medicine （Baltimore），2015，94（24）：e975.
Han B，Li K，Wang Q，et al.Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer：The ALTER 0303 Phase 3 Randomized Clinical Trial[J].JAMA Oncol，2018，4（11）：1569-1575.
[9]
He C，Wu T，Hao Y.Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway[J].Biochem Biophys Res Commun，2018，503（4）：3093-3099.
[10]
Sun Y，Du F，Gao M，et al.Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J].Thyroid，2018，28（11）：1455-1461.
[11]
Ruan X，Shi X，Dong Q，et al.Antitumor effects of anlotinib in thyroid cancer[J].Endocr Relat Cancer，2019，26（1）：153-164.
[12]
Chi Y，Fang Z，Hong X，et al.Safety and Efficacy of Anlotinib，a Multikinase Angiogenesis Inhibitor，in Patients with Refractory Metastatic Soft-Tissue Sarcoma[J].Clin Cancer Res，2018，24（21）：5233-5238.
Costa DB，Shaw AT，Ou SH，et al.Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases[J].J Clin Oncol，2015，33（17）：1881-1888.
京公网安备 11010502046607号